Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer
The purpose of this study is to determine if Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) scans used in this study accurate and better at imaging participants' prostate cancer than the usual methods.
Prostate Cancer|Prostate Neoplasm|Prostate Adenocarcinoma|Prostate Cancer Metastatic|Metastatic Prostate Cancer
DRUG: 18F-DCFPyL-iPSMA|DRUG: 68Ga-HBED-iPSMA|DIAGNOSTIC_TEST: PET/CT scan
Measure predictive accuracy of the change in PSMA PET with respect to the time to biochemical progression, start of treatment to the first PSA level above 0.2 ng/ml, up to 100 months|Measure predictive accuracy of the change in PSMA PET with respect to the time to metastasis, Time from the start of treatment to evidence of systemic disease on bone scan or CT/MRI, up to 100 months|Measure predictive accuracy of the change in PSMA PET with respect to overall survival time., Time from the start of treatment to date of death from any cause, assessed up to up to 100 months
The purpose of this study is to determine if Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) scans used in this study accurate and better at imaging participants' prostate cancer than the usual methods.